{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:06Z","timestamp":1792097046905,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["PJT-198035"],"award-info":[{"award-number":["PJT-198035"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["PJT-192035"],"award-info":[{"award-number":["PJT-192035"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chembiol.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:42:19Z","timestamp":1792075339000},"page":"1443-1458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting protein arginine methyltransferases to enhance cancer immunotherapy"],"prefix":"10.1016","volume":"33","author":[{"given":"Nivine","family":"Srour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4806","authenticated-orcid":false,"given":"St\u00e9phane","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2026.09.010_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.70011","article-title":"Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody-Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects","volume":"42","author":"Li","year":"2024","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.chembiol.2026.09.010_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2026.09.010_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.09.010_bib8","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib10","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.09.010_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2026.09.010_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.chembiol.2026.09.010_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s43018-024-00889-9","article-title":"Systemic IFN-I combined with topical TLR7\/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells","volume":"6","author":"Sanlorenzo","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2026.09.010_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado4370","article-title":"The mRNA export pathway licenses viral mimicry response and antitumor immunity by actively exporting nuclear retroelement transcripts","volume":"17","author":"Wang","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib16","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","article-title":"Cellular pathways influenced by protein arginine methylation: Implications for cancer","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/srep01311","article-title":"Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs","volume":"3","author":"Dhar","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2026.09.010_bib18","doi-asserted-by":"crossref","first-page":"37010","DOI":"10.1074\/jbc.M113.525345","article-title":"Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions","volume":"288","author":"Feng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.09.010_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.abb.2019.02.014","article-title":"PRMT7 as a unique member of the protein arginine methyltransferase family: A review","volume":"665","author":"Jain","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.chembiol.2026.09.010_bib20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.09.010_bib21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.09.010_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2026.09.010_bib23","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2026.09.010_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2026.09.010_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.molcel.2013.05.021","article-title":"Defining the RGG\/RG motif","volume":"50","author":"Thandapani","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.chembiol.2026.09.010_bib29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-022-05545-9","article-title":"R-loop-derived cytoplasmic RNA-DNA hybrids activate an immune response","volume":"613","author":"Crossley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2026.09.010_bib31","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-023-38443-3","article-title":"PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081600","article-title":"Signaling by Type I Interferons in Immune Cells: Disease Consequences","volume":"16","author":"Zannikou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.chembiol.2026.09.010_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051037","article-title":"Type I and II Interferons in the Anti-Tumor Immune Response","volume":"13","author":"Fenton","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.chembiol.2026.09.010_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1834","article-title":"Arginine methyltransferase PRMT5 negatively regulates cGAS-mediated antiviral immune response","volume":"7","author":"Ma","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chembiol.2026.09.010_bib35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214956120","article-title":"Asymmetric arginine dimethylation of cytosolic RNA and DNA sensors by PRMT3 attenuates antiviral innate immunity","volume":"120","author":"Zhu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2026.09.010_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113831","article-title":"PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity","volume":"43","author":"Djajawi","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2026.09.010_bib37","doi-asserted-by":"crossref","first-page":"7930","DOI":"10.1038\/s41467-024-52170-3","article-title":"Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS\/STING signaling","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116547","article-title":"ID1 boosts antiviral immunity by countering PRMT5-mediated STING methylation","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2026.09.010_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010639","article-title":"Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer","volume":"13","author":"Duan","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib41","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/s41467-024-47107-9","article-title":"Loss-of-function mutation in PRMT9 causes abnormal synapse development by dysregulation of RNA alternative splicing","volume":"15","author":"Shen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib42","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1038\/ncomms7428","article-title":"PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s43018-024-00736-x","article-title":"Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity","volume":"5","author":"Dong","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2025.05.007","article-title":"Epigenetically targeting PRMT5 promotes antitumor immunity by inducing endogenous retroviruses expression and triggering viral mimicry response","volume":"281","author":"Zhang","year":"2025","journal-title":"Transl. Res."},{"key":"10.1016\/j.chembiol.2026.09.010_bib45","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.molcel.2021.06.004","article-title":"Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity","volume":"81","author":"Zhu","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408117121","article-title":"Targeting PRMT7-mediated monomethylation of MAVS enhances antiviral innate immune responses and inhibits RNA virus replication","volume":"121","author":"Yang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2026.09.010_bib47","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-022-32628-y","article-title":"The protein arginine methyltransferase PRMT9 attenuates MAVS activation through arginine methylation","volume":"13","author":"Bai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/CIRCULATIONAHA.125.076101","article-title":"Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1","volume":"153","author":"Bai","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.chembiol.2026.09.010_bib49","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/2159-8290.CD-20-1144","article-title":"CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells","volume":"11","author":"Kumar","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2026.09.010_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006107","article-title":"XRN2 Links Transcription Termination to DNA Damage and Replication Stress","volume":"12","author":"Morales","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.chembiol.2026.09.010_bib51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1090077","article-title":"Pharmacological DNA demethylation: Implications for cancer immunotherapy","volume":"5","author":"Roulois","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.chembiol.2026.09.010_bib53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib54","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107713","article-title":"Alternative splicing: A key regulator in T cell response and cancer immunotherapy","volume":"215","author":"Yong","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.chembiol.2026.09.010_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nsmb.1568","article-title":"PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing","volume":"16","author":"Zhao","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib57","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.2147\/JIR.S364190","article-title":"The Influence of Arginine Methylation in Immunity and Inflammation","volume":"15","author":"Srour","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.chembiol.2026.09.010_bib58","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1096\/fj.201902569R","article-title":"Zebrafish prmt3 negatively regulates antiviral responses","volume":"34","author":"Zhu","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.chembiol.2026.09.010_bib59","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41423-018-0057-4","article-title":"The methyltransferase PRMT6 attenuates antiviral innate immunity by blocking TBK1-IRF3 signaling","volume":"16","author":"Zhang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2022.104351","article-title":"Grass carp PRMT6 negatively regulates innate immunity by inhibiting the TBK1\/IRF3 binding and cutting down IRF3 phosphorylation level","volume":"129","author":"Jiang","year":"2022","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-77155-2","article-title":"T7 restricts CD8+ T cells expansion via the NF-kB pathway","author":"Srour","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22088","article-title":"Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.chembiol.2026.09.010_bib64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.09.010_bib65","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659093","article-title":"Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients","volume":"9","author":"Gide","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.chembiol.2026.09.010_bib67","article-title":"Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities","volume":"4","author":"Liu","year":"2024","journal-title":"Cell Genom."},{"key":"10.1016\/j.chembiol.2026.09.010_bib68","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2026.09.010_bib70","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/acschembio.5b00839","article-title":"A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases","volume":"11","author":"Eram","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib73","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.2025.43.16_suppl.3082","article-title":"Preliminary efficacy results from an ongoing phase I\/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced\/metastatic solid tumors","volume":"43","author":"Jin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117625","article-title":"Discovery of a first-in-class protein arginine methyltransferase 1 (PRMT1) degrader for nonenzymatic functions studies","volume":"291","author":"Ma","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.09.010_bib75","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1002\/anie.201412154","article-title":"A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3)","volume":"54","author":"Kaniskan","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.chembiol.2026.09.010_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405963","article-title":"Discovery of PRMT3 Degrader for the Treatment of Acute Leukemia","volume":"11","author":"Zou","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.chembiol.2026.09.010_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18446-z","article-title":"Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma","volume":"7","author":"Drew","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2026.09.010_bib78","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1021\/acs.jmedchem.3c00982","article-title":"Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.09.010_bib79","doi-asserted-by":"crossref","first-page":"13973","DOI":"10.1021\/acs.jmedchem.5c01022","article-title":"Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo","volume":"68","author":"Ju","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.09.010_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib81","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.chembiol.2026.09.010_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol."},{"key":"10.1016\/j.chembiol.2026.09.010_bib92","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41375-025-02515-8","article-title":"Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies","volume":"39","author":"Bewersdorf","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.chembiol.2026.09.010_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.chembiol.2026.09.010_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1538-7445.AM2025-4229","article-title":"GTA182: A potentially best-in-class, MTA-cooperative PRMT5 inhibitor for MTAP-deleted advanced solid tumors Free","volume":"85","author":"Mao","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.09.010_bib85","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0969-2126(03)00071-6","article-title":"Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides","volume":"11","author":"Zhang","year":"2003","journal-title":"Structure"},{"key":"10.1016\/j.chembiol.2026.09.010_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2025.2600946","article-title":"Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)","volume":"36","author":"Viviano","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.chembiol.2026.09.010_bib87","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2026.09.010_bib88","article-title":"Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy","volume":"7","author":"Sun","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.chembiol.2026.09.010_bib89","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/acs.jmedchem.5c00198","article-title":"Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader","volume":"68","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.09.010_bib90","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41467-020-16271-z","article-title":"Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response","volume":"11","author":"Szewczyk","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.09.010_bib91","doi-asserted-by":"crossref","first-page":"8244","DOI":"10.1021\/acs.jmedchem.4c02978","article-title":"Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626003570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626003570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:46:29Z","timestamp":1792093589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945626003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2451945626003570"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.09.010","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting protein arginine methyltransferases to enhance cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}